Bayer Aktiengesellschaft
BAYN
株式のランク
#489
Bayer Aktiengesellschaft operates as a life science company in Europe, the... Bayer Aktiengesellschaft operates as a life science company in Europe, the Middle East, Africa, Germany, Switzerland, North America, the United States, the Asia Pacific, China, Latin America, and Brazil. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment provides prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment offers nonprescription over-the-counter medicines for self-medication and self-care; nutritional supplements; allergy, cough, and cold; dermatology; pain and cardiovascular risk prevention; and digestive health products. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solutions, and pest and weed management products, as well as customer services for agriculture. It also engages in the breeding, propagation, and production/processing of seeds, including seed dressing. The company distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. Bayer Aktiengesellschaft was founded in 1863 and is based in Leverkusen, Germany.
株価
$50.31
最終同期: 2026-10-21
時価総額
$49.43B
変化（1日）
-2.45%
変化（1年）
57.43%
国
DE
取引 Bayer Aktiengesellschaft (BAYN)
カテゴリー
Healthcare
Bayer Aktiengesellschaft（BAYN）の収益
Oct 2026 時点の収益 TTM: 0
Bayer Aktiengesellschaft の最新の財務報告によると、現在の収益 (TTM) は 0 です。2026 年には 0 の収益があり、これは 2026 年の 0 と比較して 同等 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
Bayer Aktiengesellschaft の収益履歴（2026 ～ 2026）
各年末の収益
| 年 | 収益 | 変化 |
|---|---|---|
| 提供された日付のデータは十分ではありません。 | ||
同業他社の収益
| 企業 | 収益 | 収益の差 | 国 |
|---|---|---|---|
| $79.67B | - |
US
|
|
| $99.34B | - |
US
|
|
| $64.39B | - |
US
|
|
| $66.40B | - |
US
|
|
| $77.52B | - |
CH
|
